- Home
- LKFN vs PCRX Comparison
LKFN vs PCRX Comparison
Compare LKFN & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LKFN
- PCRX
- Stock Information
- Founded
- LKFN 1872
- PCRX 2006
- Country
- LKFN United States
- PCRX United States
- Employees
- LKFN N/A
- PCRX N/A
- Industry
- LKFN Major Banks
- PCRX Biotechnology: Pharmaceutical Preparations
- Sector
- LKFN Finance
- PCRX Health Care
- Exchange
- LKFN Nasdaq
- PCRX Nasdaq
- Market Cap
- LKFN 1.3B
- PCRX 1.2B
- IPO Year
- LKFN 1997
- PCRX 2011
- Fundamental
- Price
- LKFN $60.90
- PCRX $24.45
- Analyst Decision
- LKFN Buy
- PCRX Buy
- Analyst Count
- LKFN 2
- PCRX 9
- Target Price
- LKFN $65.00
- PCRX $29.89
- AVG Volume (30 Days)
- LKFN 234.3K
- PCRX 870.2K
- Earning Date
- LKFN 04-25-2025
- PCRX 05-08-2025
- Dividend Yield
- LKFN 3.27%
- PCRX N/A
- EPS Growth
- LKFN N/A
- PCRX N/A
- EPS
- LKFN 3.50
- PCRX N/A
- Revenue
- LKFN $236,268,000.00
- PCRX $702,772,000.00
- Revenue This Year
- LKFN $16.03
- PCRX $9.48
- Revenue Next Year
- LKFN $4.31
- PCRX $11.31
- P/E Ratio
- LKFN $17.56
- PCRX N/A
- Revenue Growth
- LKFN N/A
- PCRX 3.08
- 52 Week Low
- LKFN $50.00
- PCRX $11.16
- 52 Week High
- LKFN $78.61
- PCRX $31.67
- Technical
- Relative Strength Index (RSI)
- LKFN 63.29
- PCRX 45.40
- Support Level
- LKFN $59.02
- PCRX $23.23
- Resistance Level
- LKFN $62.34
- PCRX $26.26
- Average True Range (ATR)
- LKFN 1.69
- PCRX 1.27
- MACD
- LKFN 0.78
- PCRX -0.28
- Stochastic Oscillator
- LKFN 88.33
- PCRX 33.41
About LKFN Lakeland Financial Corporation
Lakeland Financial Corp is a bank holding company. It provides commercial, retail, wealth advisory, and investment management services. Lakeland offers a broad range of products and services throughout its Northern and Central Indiana markets. The company offers commercial and consumer banking services, as well as trust and wealth management, brokerage, and treasury management commercial services. It serves a wide variety of industries including, among others, commercial real estate, manufacturing, agriculture, construction, retail, wholesale, finance and insurance, accommodation and food services, and healthcare.
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.